Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Launched by CHINESE ACADEMY OF SCIENCES · Feb 1, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to predict the risk of peritoneal metastasis in patients with advanced gastric cancer. Peritoneal metastasis occurs when cancer spreads to the lining of the abdomen, which can be hard to detect early. The study aims to develop an intelligent system that analyzes CT scan images to find specific patterns (called radiomics features) associated with this type of cancer spread. By identifying these patterns, the system hopes to help doctors make more personalized treatment decisions for patients.

To participate in this trial, individuals must be diagnosed with advanced gastric cancer verified by a biopsy and have undergone both a special CT scan and laparoscopy (a minimally invasive surgery). They should not have any obvious signs of peritoneal metastasis on their CT scans or evidence of cancer spreading to other parts of the body. Participants can expect to contribute to important research that could improve the early detection of peritoneal metastasis, potentially leading to better treatment outcomes for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and/or endoscopic ultrasound;
• • (2) with both enhanced CT and laparoscopy;
• • (3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement);
• • (4) without other evidence of distant metastasis, and no stage IV features on CT.
• Exclusion Criteria:
• • (1) previous abdominal surgery;
• • (2) previous abdominal malignancies or inflammatory diseases;
• • (3) time intervals between CT and laparoscopy longer than 2 weeks;
• • (4) CT image artifacts that undermine peritoneal lesion assessment.